JP2003513073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003513073A5 JP2003513073A5 JP2001534774A JP2001534774A JP2003513073A5 JP 2003513073 A5 JP2003513073 A5 JP 2003513073A5 JP 2001534774 A JP2001534774 A JP 2001534774A JP 2001534774 A JP2001534774 A JP 2001534774A JP 2003513073 A5 JP2003513073 A5 JP 2003513073A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- hydroxy
- indole
- carboxamide
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 18
- 239000001257 hydrogen Substances 0.000 description 18
- 150000002431 hydrogen Chemical class 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000006735 deficit Effects 0.000 description 8
- 229960002715 nicotine Drugs 0.000 description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 208000000044 Amnesia Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 4
- 208000020925 Bipolar disease Diseases 0.000 description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000023105 Huntington disease Diseases 0.000 description 4
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 4
- 208000009829 Lewy Body Disease Diseases 0.000 description 4
- 201000002832 Lewy body dementia Diseases 0.000 description 4
- 206010026749 Mania Diseases 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 208000000323 Tourette Syndrome Diseases 0.000 description 4
- 208000016620 Tourette disease Diseases 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000003935 attention Effects 0.000 description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 208000028683 bipolar I disease Diseases 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 230000007278 cognition impairment Effects 0.000 description 4
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 4
- 230000006984 memory degeneration Effects 0.000 description 4
- 208000023060 memory loss Diseases 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 206010057852 Nicotine dependence Diseases 0.000 description 3
- 208000025569 Tobacco Use disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 230000005586 smoking cessation Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- -1 (4-benzyl) oxazolin-2-yl Chemical group 0.000 description 1
- YCZADCRYQVJCLW-UHFFFAOYSA-N (4-hydroxy-1-methylindol-2-yl)-pyrrolidin-1-ylmethanone Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)N1CCCC1 YCZADCRYQVJCLW-UHFFFAOYSA-N 0.000 description 1
- HCMUPTQEYTYGHB-UHFFFAOYSA-N 4-hydroxy-1-methyl-n-(2-phenylethyl)indole-2-carboxamide Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)NCCC1=CC=CC=C1 HCMUPTQEYTYGHB-UHFFFAOYSA-N 0.000 description 1
- XMXWFSWWQPUYDJ-UHFFFAOYSA-N 4-hydroxy-1-methyl-n-(3-phenylpropyl)indole-2-carboxamide Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)NCCCC1=CC=CC=C1 XMXWFSWWQPUYDJ-UHFFFAOYSA-N 0.000 description 1
- VNUZXARZRWELJO-UHFFFAOYSA-N 4-hydroxy-1-methyl-n-(4-phenylbutyl)indole-2-carboxamide Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)NCCCCC1=CC=CC=C1 VNUZXARZRWELJO-UHFFFAOYSA-N 0.000 description 1
- FTFBINRINIORBJ-UHFFFAOYSA-N 4-hydroxy-1-methyl-n-phenylindole-2-carboxamide Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)NC1=CC=CC=C1 FTFBINRINIORBJ-UHFFFAOYSA-N 0.000 description 1
- QTAABPDKPSKCNJ-UHFFFAOYSA-N 4-hydroxy-1-methylindole-2-carboxamide Chemical compound C1=CC=C2N(C)C(C(N)=O)=CC2=C1O QTAABPDKPSKCNJ-UHFFFAOYSA-N 0.000 description 1
- CKZLTECAOSGTBC-UHFFFAOYSA-N 4-hydroxy-1-methylindole-2-carboxylic acid Chemical compound C1=CC=C2N(C)C(C(O)=O)=CC2=C1O CKZLTECAOSGTBC-UHFFFAOYSA-N 0.000 description 1
- VIGGBSWKZAAVBB-AWEZNQCLSA-N 4-hydroxy-n-[(1r)-2-hydroxy-1-phenylethyl]-1-methylindole-2-carboxamide Chemical compound C1([C@H](CO)NC(=O)C=2N(C3=CC=CC(O)=C3C=2)C)=CC=CC=C1 VIGGBSWKZAAVBB-AWEZNQCLSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010068887 Tobacco poisoning Diseases 0.000 description 1
- 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- XRGYOXWBAUCLAX-AWEZNQCLSA-N diazonio-[(2s)-2-[(4-hydroxy-1-methylindole-2-carbonyl)amino]-3-phenylpropyl]azanide Chemical compound C([C@@H](CN=[N+]=[N-])NC(=O)C=1N(C2=CC=CC(O)=C2C=1)C)C1=CC=CC=C1 XRGYOXWBAUCLAX-AWEZNQCLSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NCFRPTLPGWKEIX-UHFFFAOYSA-N ethyl 4-hydroxy-1-methylindole-2-carboxylate Chemical compound C1=CC=C2N(C)C(C(=O)OCC)=CC2=C1O NCFRPTLPGWKEIX-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- HGHBXVSSWNDWGV-UHFFFAOYSA-N n-(1-fluoro-3-phenylpropan-2-yl)-4-hydroxy-1-methylindole-2-carboxamide Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)NC(CF)CC1=CC=CC=C1 HGHBXVSSWNDWGV-UHFFFAOYSA-N 0.000 description 1
- UWEAINNLPOKQDF-UHFFFAOYSA-N n-(2-fluoroethyl)-4-hydroxy-1-methylindole-2-carboxamide Chemical compound C1=CC=C2N(C)C(C(=O)NCCF)=CC2=C1O UWEAINNLPOKQDF-UHFFFAOYSA-N 0.000 description 1
- MPKQMEXBCWRJSI-UHFFFAOYSA-N n-(4-chlorophenyl)-4-hydroxy-1-methylindole-2-carboxamide Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)NC1=CC=C(Cl)C=C1 MPKQMEXBCWRJSI-UHFFFAOYSA-N 0.000 description 1
- VSDMPNPFAOTDRA-CQSZACIVSA-N n-[(2r)-2-fluoro-3-phenylpropyl]-4-hydroxy-1-methylindole-2-carboxamide Chemical compound C([C@@H](F)CNC(=O)C=1N(C2=CC=CC(O)=C2C=1)C)C1=CC=CC=C1 VSDMPNPFAOTDRA-CQSZACIVSA-N 0.000 description 1
- DISOOVOIBKFPCC-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-hydroxy-1-methylindole-2-carboxamide Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)NCC1=CC=C(Cl)C=C1 DISOOVOIBKFPCC-UHFFFAOYSA-N 0.000 description 1
- GDXAEGSNSMJISF-UHFFFAOYSA-N n-[[4-(dimethylamino)phenyl]methyl]-4-hydroxy-1-methylindole-2-carboxamide Chemical compound C1=CC(N(C)C)=CC=C1CNC(=O)C1=CC2=C(O)C=CC=C2N1C GDXAEGSNSMJISF-UHFFFAOYSA-N 0.000 description 1
- NHZLWLAHJVXVQW-UHFFFAOYSA-N n-benzyl-4-hydroxy-1-methylindole-2-carboxamide Chemical compound C=1C2=C(O)C=CC=C2N(C)C=1C(=O)NCC1=CC=CC=C1 NHZLWLAHJVXVQW-UHFFFAOYSA-N 0.000 description 1
- JQKJBEJXYCWGPM-UHFFFAOYSA-N n-ethyl-4-hydroxy-1-methylindole-2-carboxamide Chemical compound C1=CC=C2N(C)C(C(=O)NCC)=CC2=C1O JQKJBEJXYCWGPM-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9903998-4 | 1999-11-03 | ||
| SE9903998A SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | New compounds |
| PCT/SE2000/002147 WO2001032622A1 (en) | 1999-11-03 | 2000-11-01 | Positive modulators of nicotinic receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003513073A JP2003513073A (ja) | 2003-04-08 |
| JP2003513073A5 true JP2003513073A5 (cg-RX-API-DMAC7.html) | 2007-11-22 |
Family
ID=20417608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001534774A Abandoned JP2003513073A (ja) | 1999-11-03 | 2000-11-01 | ニコチン受容体作用薬の正のモジュレーター |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7064143B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1230218A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2003513073A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20020063175A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1216864C (cg-RX-API-DMAC7.html) |
| AU (1) | AU783602B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0015193A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2387741A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO5280079A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL149096A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA02004240A (cg-RX-API-DMAC7.html) |
| NO (1) | NO323077B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ518449A (cg-RX-API-DMAC7.html) |
| SE (1) | SE9903998D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001032622A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200203181B (cg-RX-API-DMAC7.html) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030162825A1 (en) * | 2001-11-09 | 2003-08-28 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| EP1531820A1 (en) | 2002-08-30 | 2005-05-25 | Memory Pharmaceuticals Corporation | Anabaseine derivatives useful in the treatment of neurodegenerative diseases |
| MXPA05003317A (es) | 2002-09-25 | 2005-07-05 | Memory Pharm Corp | Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos. |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
| WO2005066135A2 (en) | 2003-12-29 | 2005-07-21 | Sepracor Inc. | Pyrrole and pyrazole daao inhibitors |
| JP2007527904A (ja) | 2004-03-08 | 2007-10-04 | プロシディオン・リミテッド | グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物 |
| RU2417225C2 (ru) | 2004-03-25 | 2011-04-27 | Мемори Фармасьютиклз Корпорейшн | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение |
| WO2005118539A1 (en) | 2004-06-01 | 2005-12-15 | F.Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| JP5254616B2 (ja) | 2004-09-13 | 2013-08-07 | クロノ セラピューティクス、インコーポレイテッド | 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達 |
| WO2006055462A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7214704B2 (en) | 2004-11-15 | 2007-05-08 | Bristol-Myers Squibb Company | 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006059164A2 (en) | 2004-12-02 | 2006-06-08 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amides |
| FR2888847B1 (fr) | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| BRPI0619263A2 (pt) | 2005-11-30 | 2011-09-27 | Hoffmann La Roche | indóis de 3-amino-1-arilpropila e indóis aza-substituìdos, métodos para prepará-los, composição farmacêutica e uso dos referidos indóis |
| CA2631048A1 (en) | 2005-11-30 | 2007-06-07 | F. Hoffmann-La Roche Ag | Methods for synthesis of 3-amino-1-arylpropyl indoles |
| JP2009517432A (ja) | 2005-11-30 | 2009-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | ３−アミノ−２−アリールプロピルアザインドールおよびその使用 |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| WO2008083729A1 (en) * | 2007-01-09 | 2008-07-17 | Bayer Schering Pharma Aktiengesellschaft | Radiolabelling via fluorination of aziridines |
| EP1944288A1 (en) * | 2007-01-09 | 2008-07-16 | Bayer Schering Pharma Aktiengesellschaft | Radiolabelling via fluorination of aziridines |
| JP2010523587A (ja) * | 2007-04-02 | 2010-07-15 | パーキンソンズ インスティテュート | 治療処置の副作用の低減のための方法および組成物 |
| US8383657B2 (en) | 2007-12-21 | 2013-02-26 | Abbott Laboratories | Thiazolylidine urea and amide derivatives and methods of use thereof |
| DK3029039T3 (en) | 2010-05-17 | 2017-12-04 | Forum Pharmaceuticals Inc | PHARMACEUTICAL FORMS CONTAINING CRYSTALLINIC FORMS OF (R) -7-CHLOR-N- (QUINUCLIDIN-3-YL) BENZO (B) THIOPHEN-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE |
| AR085509A1 (es) | 2011-03-09 | 2013-10-09 | Bayer Cropscience Ag | Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas |
| EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON |
| CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
| EP3250258A4 (en) | 2015-01-28 | 2018-09-05 | Chrono Therapeutics, Inc. | Drug delivery methods and systems |
| WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
| EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| WO2019232077A1 (en) | 2018-05-29 | 2019-12-05 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE758766A (fr) | 1969-11-17 | 1971-05-10 | Ici Ltd | Nouveaux derives de la morpholine et de la |
| US4704390A (en) * | 1986-02-13 | 1987-11-03 | Warner-Lambert Company | Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents |
| KR930702334A (ko) | 1990-09-13 | 1993-09-08 | 데이비드 로버트 | 5 하이드록시트립타민 수용체 길항제로서의 인돌우레아 |
| ATE190608T1 (de) | 1991-11-25 | 2000-04-15 | Pfizer | 5-(hetero- oder carbocyclylamino)-indol derivate, deren herstellung und deren verwendung als 5-ht1 agonisten |
| WO1993018026A1 (en) | 1992-03-04 | 1993-09-16 | Beecham Group Plc | Indole ureas as 5-ht1c receptor antogonists |
| US5504101A (en) * | 1994-05-06 | 1996-04-02 | Allelix Biopharmaceuticals, Inc. | 5-HT-1D receptor ligands |
| FR2722686B1 (fr) * | 1994-07-22 | 1996-08-30 | Oreal | Set, procede, dispositif et composition de teinture des fibres keratiniques |
| US5576321A (en) * | 1995-01-17 | 1996-11-19 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
| SE9903997D0 (sv) * | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
-
1999
- 1999-11-03 SE SE9903998A patent/SE9903998D0/xx unknown
-
2000
- 2000-11-01 NZ NZ518449A patent/NZ518449A/en unknown
- 2000-11-01 AU AU14263/01A patent/AU783602B2/en not_active Ceased
- 2000-11-01 WO PCT/SE2000/002147 patent/WO2001032622A1/en not_active Ceased
- 2000-11-01 BR BR0015193-9A patent/BR0015193A/pt not_active IP Right Cessation
- 2000-11-01 JP JP2001534774A patent/JP2003513073A/ja not_active Abandoned
- 2000-11-01 CA CA002387741A patent/CA2387741A1/en not_active Abandoned
- 2000-11-01 CN CN008154406A patent/CN1216864C/zh not_active Expired - Fee Related
- 2000-11-01 US US10/111,029 patent/US7064143B1/en not_active Expired - Fee Related
- 2000-11-01 CO CO00083137A patent/CO5280079A1/es not_active Application Discontinuation
- 2000-11-01 EP EP00976499A patent/EP1230218A1/en not_active Withdrawn
- 2000-11-01 KR KR1020027005705A patent/KR20020063175A/ko not_active Ceased
- 2000-11-01 IL IL14909600A patent/IL149096A0/xx unknown
- 2000-11-01 MX MXPA02004240A patent/MXPA02004240A/es not_active Application Discontinuation
-
2002
- 2002-04-22 ZA ZA200203181A patent/ZA200203181B/xx unknown
- 2002-05-02 NO NO20022105A patent/NO323077B1/no unknown
-
2005
- 2005-07-11 US US11/178,668 patent/US7402604B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003513073A5 (cg-RX-API-DMAC7.html) | ||
| JP2003513071A5 (cg-RX-API-DMAC7.html) | ||
| JP2003512374A5 (cg-RX-API-DMAC7.html) | ||
| JP2003514818A5 (cg-RX-API-DMAC7.html) | ||
| JP2010509356A5 (cg-RX-API-DMAC7.html) | ||
| JP2007517807A5 (cg-RX-API-DMAC7.html) | ||
| HU900671D0 (en) | Process for preparation of heterociclyc compounds containing fused benzene-rings and nitrogen atom | |
| JP2008509187A5 (cg-RX-API-DMAC7.html) | ||
| AR045083A1 (es) | Productos aril-heteroaromaticos, composiciones que los contienen y utilizacion como medicamento | |
| AU2018204290B2 (en) | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | |
| CA2466965A1 (en) | Sulphonamide derivatives, their preparation and use as medicaments | |
| JP2006507241A5 (cg-RX-API-DMAC7.html) | ||
| NO2013002I2 (no) | Aklidiniumsalt med et farmaøytisk akseptabelt anion av en mono-eller polyvalent syre, spesielt aklidiniumbromid | |
| JP2002501025A5 (cg-RX-API-DMAC7.html) | ||
| ATE231394T1 (de) | Heterozyklische piperazinyl verbindungen zur behandlung von demenz | |
| DE69912808D1 (de) | Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel | |
| JP2007532637A5 (cg-RX-API-DMAC7.html) | ||
| DE69418789D1 (de) | 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren | |
| JP2005508872A5 (cg-RX-API-DMAC7.html) | ||
| DE69705817D1 (de) | (N-(Pyridinylmethyl)-heterozyklische)-ylidenamin-Derivate als Nikotin-Acetylcholin-Rezeptor-Bindemittel | |
| JP2007515479A5 (cg-RX-API-DMAC7.html) | ||
| RU2006125636A (ru) | Лиганды никотиновых рецепторов ацетилхолина | |
| JP2003513072A5 (cg-RX-API-DMAC7.html) | ||
| JP2009508876A5 (cg-RX-API-DMAC7.html) | ||
| JP2006506319A5 (cg-RX-API-DMAC7.html) |